Adults with Philadelphia chromosome-like acute lymphoblastic leukemia frequently have IGH-CRLF2 and JAK2 mutations, persistence of minimal residual disease and poor prognosis

被引:112
|
作者
Herold, Tobias [1 ,2 ,3 ]
Schneider, Stephanie [1 ]
Metzeler, Klaus H. [1 ,2 ,3 ]
Neumann, Martin [1 ,2 ,3 ,4 ]
Hartmann, Luise [1 ,2 ,3 ]
Roberts, Kathryn G. [5 ]
Konstandin, Nikola P. [1 ]
Greif, Philipp A. [1 ,2 ,3 ]
Braeundl, Kathrin [1 ,2 ,3 ]
Ksienzyk, Bianka [1 ]
Huk, Natalia [1 ]
Schneider, Irene [1 ]
Zellmeier, Evelyn [1 ]
Jurinovic, Vindi [6 ]
Mansmann, Ulrich [6 ]
Hiddemann, Wolfgang [1 ,2 ,3 ]
Mullighan, Charles G. [5 ]
Bohlander, Stefan K. [7 ]
Spiekermann, Karsten [1 ,2 ,3 ]
Hoelzer, Dieter [8 ]
Bruggemann, Monika [9 ]
Baldus, Claudia D. [2 ,3 ,4 ]
Dreyling, Martin [1 ]
Goekbuget, Nicola [8 ]
机构
[1] LMU, Univ Hosp Grosshadern, Dept Internal Med 3, Munich, Germany
[2] German Canc Consortium DKTK, Heidelberg, Germany
[3] German Canc Res Ctr, Heidelberg, Germany
[4] Charite Univ Med Berlin, Dept Hematol Oncol & Tumor Immunol, Berlin, Germany
[5] St Jude Childrens Res Hosp, Dept Pathol, 332 N Lauderdale St, Memphis, TN 38105 USA
[6] LMU, Inst Med Informat Biometry & Epidemiol, Munich, Germany
[7] Univ Auckland, Dept Mol Med & Pathol, Auckland, New Zealand
[8] Goethe Univ Hosp, Dept Med 2, Frankfurt, Germany
[9] Univ Hosp Schleswig Holstein, Dept Hematol, Campus Kiel, Kiel, Germany
关键词
READ ALIGNMENT; EXPRESSION; SIGNATURE; SUBGROUP; CHILDREN; SURVIVAL; DELETION; KINASE; IKZF1; MRD;
D O I
10.3324/haematol.2015.136366
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Philadelphia-like B-cell precursor acute lymphoblastic leukemia (Ph-like ALL) is characterized by distinct genetic alterations and inferior prognosis in children and younger adults. The purpose of this study was a genetic and clinical characterization of Ph-like ALL in adults. Twenty-six (13%) of 207 adult patients (median age: 42 years) with B-cell precursor ALL (BCP-ALL) were classified as having Ph-like ALL using gene expression profiling. The frequency of Ph-like ALL was 27% among 95 BCP-ALL patients negative for BCR-ABL1 and KMT2A-rearrangements. IGH-CRLF2 rearrangements (6/16; P=0.002) and mutations in JAK2 (7/16; P<0.001) were found exclusively in the Ph-like ALL subgroup. Clinical and outcome analyses were restricted to patients treated in German Multicenter Study Group for Adult ALL (GMALL) trials 06/99 and 07/03 (n=107). The complete remission rate was 100% among both Ph-like ALL patients (n=19) and the "remaining BCP-ALL" cases (n=40), i.e. patients negative for BCR-ABL1 and KMT2A-rearrangements and the Ph-like subtype. Significantly fewer Ph-like ALL patients reached molecular complete remission (33% versus 79%; P=0.02) and had a lower probability of continuous complete remission (26% versus 60%; P=0.03) and overall survival (22% versus 64%; P=0.006) at 5 years compared to the remaining BCP-ALL patients. The profile of genetic lesions in adults with Ph-like ALL, including older adults, resembles that of pediatric Ph-like ALL and differs from the profile in the remaining BCP-ALL. Our study is the first to demonstrate that Ph-like ALL is associated with inferior outcomes in intensively treated older adult patients. Ph-like adult ALL should be recognized as a distinct, high-risk entity and further research on improved diagnostic and therapeutic approaches is needed. (NCT00199056, NCT00198991)
引用
收藏
页码:130 / 138
页数:9
相关论文
共 50 条
  • [41] A Phase 2 Study of Dasatinib, Prednisone, and Blinatumomab for Older Patients with Philadelphia-Chromosome (Ph) Positive or Ph-like Acute Lymphoblastic Leukemia (ALL) (with Dasatinib Sensitive Fusions/ Mutations)
    Advani, Anjali
    Moseley, Anna
    O'Dwyer, Kristen
    Wood, Brent
    Park, Jae H.
    Wieduwilt, Matthew
    Jeyakumar, Deepa
    Yaghmour, George
    Atallah, Ehab L.
    Gerds, Aaron T.
    O'Brien, Susan M.
    Liesveld, Jane L.
    Othus, Megan
    Litzow, Mark R.
    Stone, Richard M.
    Sharon, Elad
    Erba, Harry P.
    BLOOD, 2021, 138
  • [42] Rapid Minimal Residual Disease Clearance with More Stringent Age-Related Dose Criteria Improves Prognosis in Infants with KMT2A-Rearranged Acute Lymphoblastic Leukemia
    Ishihara, T.
    Arakawa, Y.
    Miyamura, T.
    Nogami, Y.
    Ishimaru, S.
    Takachi, T.
    Yano, M.
    Sasaki, S.
    Saito, A.
    Deguchi, T.
    Hori, T.
    Yamada, T.
    Sanada, M.
    Manabe, A.
    Horibe, K.
    Imamura, T.
    Tomizawa, D.
    PEDIATRIC BLOOD & CANCER, 2021, 68 : S89 - S89
  • [43] Sustained remission after ruxolitinib and chimeric antigen receptor T-cell therapy bridged to a second allogeneic hematopoietic stem cell transplantation for relapsed Philadelphia chromosome-like B-cell precursor acute lymphoblastic leukemia with novel NPHP3-JAK2 fusion
    Chen, Xue
    Yuan, Lili
    Zhou, Jiarui
    Wang, Fang
    Zhang, Yang
    Ma, Xiaoli
    Cao, Panxiang
    Fang, Jiancheng
    Chen, Jiaqi
    Zhou, Xiaosu
    Wu, Qisheng
    Liu, Ming
    Liu, Hongxing
    GENES CHROMOSOMES & CANCER, 2022, 61 (01): : 55 - 58
  • [44] Treatment of High-Risk Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia in Adolescents and Adults According to Early Cytologic Response and Minimal Residual Disease After Consolidation Assessed by Flow Cytometry: Final Results of the PETHEMA ALL-AR-03 Trial
    Ribera, Josep-Maria
    Oriol, Albert
    Morgades, Mireia
    Montesinos, Pau
    Sarra, Josep
    Gonzalez-Campos, Jose
    Brunet, Salut
    Tormo, Mar
    Fernandez-Abellan, Pascual
    Guardia, Ramon
    Bernal, Maria-Teresa
    Esteve, Jordi
    Barba, Pere
    Moreno, Maria-Jose
    Bermudez, Arancha
    Cladera, Antonia
    Escoda, Lourdes
    Garcia-Boyero, Raimundo
    del Potro, Eloy
    Bergua, Juan
    Amigo, Maria-Luz
    Grande, Carlos
    Rabunal, Maria-Jose
    Hernandez-Rivas, Jesus-Maria
    Feliu, Evarist
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15) : 1595 - U102
  • [45] Minimal Residual Disease At 3 Months, Combined to the Presence of IKZF1 Deletion in B-Lineage or Absence of NOTCH1 pathway Mutation in T-Lineage, Recapitulates the Disease Risk Assessment in Adults with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia - A GRAALL Study
    Beldjord, Kheira
    Macintyre, Elizabeth
    Lheritier, Veronique
    Boulland, Marie-Laure
    Leguay, Thibaut
    Thomas, Xavier
    Cayuela, Jean-Michel
    Grardel, Nathalie
    Chalandon, Yves
    Boissel, Nicolas
    Schaefer, Beat
    Cave, Helene
    Chevallier, Patrice
    Buzyn, Agnes
    Fest, Thierry
    Asnafi, Vahid
    Reman, Oumedaly
    Bene, Marie-Christine
    Huguet, Francoise
    Chevret, Sylvie
    Ifrah, Norbert
    Dombret, Herve
    BLOOD, 2011, 118 (21) : 263 - 264
  • [46] Development and Validation of a Highly Sensitive ela2 (p190) BCR-ABL Test to Determine Complete Molecular Response (Minimal Residual Disease Negative) As a Primary Endpoint for Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph plus ALL)
    Drafahl, Kristy
    Smith, David C.
    Graham, Cristen
    Glynn, Christine
    Spittle, Cindy
    Verrow, Scott
    Rivera, Victor M.
    Srivastava, Shouryadeep
    Hawkins, Kevin
    Galderisi, Chad
    BLOOD, 2018, 132
  • [47] Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1
    H. Pfeifer
    G. Cazzaniga
    V. H. J. van der Velden
    J. M. Cayuela
    B. Schäfer
    O. Spinelli
    S. Akiki
    S. Avigad
    I. Bendit
    K. Borg
    H. Cavé
    L. Elia
    S. C. Reshmi
    G. Gerrard
    S. Hayette
    M. Hermanson
    A. Juh
    T. Jurcek
    M. C. Chillón
    C. Homburg
    G. Martinelli
    V. Kairisto
    T. Lange
    T. Lion
    M. C. Mueller
    F. Pane
    L. Rai
    C. Damm-Welk
    T. Sacha
    S. Schnittger
    T. Touloumenidou
    H. Valerhaugen
    P. Vandenberghe
    J. Zuna
    H. Serve
    E. Herrmann
    S. Markovic
    J. J. M. van Dongen
    O. G. Ottmann
    Leukemia, 2019, 33 : 1910 - 1922
  • [48] Comparable Long-Term Outcomes of Reduced-Intensity and Myeloablative Conditioning Allogeneic Hematopoietic Cell Transplantation By Minimal Residual Disease Kinetics during the Tyrosine Kinase Inhibitor-Based Chemotherapy Courses in Adults with Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia in First Remission
    Yoon, Jae-Ho
    Park, Sung-Soo
    Jeon, Young-Woo
    Lee, Sung-Eun
    Cho, Byung-Sik
    Eom, Ki-Seong
    Kim, Yoo-Jin
    Kim, Hee-Je
    Min, Chang-Ki
    Cho, Seok-Goo
    Kim, Dong-Wook
    Lee, Jong Wook
    Min, Woo-Sung
    Lee, Seok
    BLOOD, 2016, 128 (22)
  • [49] Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph plus ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1
    Pfeifer, H.
    Cazzaniga, G.
    van der Velden, V. H. J.
    Cayuele, J. M.
    Schafer, B.
    Spinelli, O.
    Akiki, S.
    Avigad, S.
    Bendit, I
    Borg, K.
    Cave, H.
    Elia, L.
    Reshmi, S. C.
    Gerrard, G.
    Hayette, S.
    Hermanson, M.
    Juh, A.
    Jurcek, T.
    Chillon, M. C.
    Homburg, C.
    Martinelli, G.
    Kairisto, V
    Langen, T.
    Lion, T.
    Mueller, M. C.
    Pane, F.
    Rai, L.
    Damm-Welk, C.
    Sacha, T.
    Schnittger, S.
    Touloumenidou, T.
    Valerhaugen, H.
    Vandenberghe, P.
    Zuna, J.
    Server, H.
    Herrmann, E.
    Markovic, S.
    van Dongen, J. J. M.
    Ottmann, O. G.
    LEUKEMIA, 2019, 33 (08) : 1910 - 1922
  • [50] The Prognosis of Children Acute Lymphoblastic Leukemia (ALL) with Minimal Residual Disease (MRD) ≥10-2 After Induction (TP1) Depends on the Prephase Response and on the Level of the MRD After Consolidation (TP2): Results of the 58951EORTC Trial
    Bertrand, Yves
    Suciu, Stefan
    Grardel, Nathalie
    Bakkus, Marleen
    Mazingue, Francoise
    Yacouben, Karima
    Uyttebroeck, Anne
    Lutz, Patrick
    Plantaz, Dominique
    Girard, Sandrine
    Dastugue, Nicole
    Benoit, Yves
    Cave, Helene
    BLOOD, 2011, 118 (21) : 1103 - 1103